期刊
NANOMEDICINE
卷 9, 期 14, 页码 2099-2108出版社
FUTURE MEDICINE LTD
DOI: 10.2217/NNM.13.201
关键词
drug delivery; glioma; irinotecan; liposome; nanoliposome; nanoparticle
资金
- NIH
- National Cancer Institute Specialized Programs of Research Excellence in Brain Tumors grant [P50-CA097257]
- Accelerated Brain Cancer Cure
Aim: We sought to evaluate nanoliposomal irinotecan as an intravenous treatment in an orthotopic brain tumor model. Materials & methods: Nanoliposomal irinotecan was administered intravenously in the intracranial U87MG brain tumor model in mice, and irinotecan and SN-38 levels were analyzed in malignant and normal tissues. Therapy studies were performed in comparison to free irinotecan and control treatments. Results: Tissue analysis demonstrated favorable properties for nanoliposomal irinotecan, including a 10.9-fold increase in tumor AUC for drug compared with free irinotecan and 35-fold selectivity for tumor versus normal tissue exposure. As a therapy for orthotopic brain tumors, nanoliposomal irinotecan showed a mean survival time of 54.2 versus 29.5 days for free irinotecan. A total of 33% of the animals receiving nanoliposomal irinotecan showed no residual tumor by study end compared with no survivors in the other groups. Conclusion: Nanoliposomal irinotecan administered systemically provides significant pharmacologic advantages and may be an efficacious therapy for brain tumors.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据